AUPH
Aurinia Pharmaceuticals Inc.Company Information
- Company Name
- Aurinia Pharmaceuticals Inc.
- CIK
- CIK0001600620
- Category
- Large accelerated filer
- Ticker: Exchange
- AUPH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AUPH
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-02
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 390,213
- Shares sold (TTM)
- 32,914
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 76,805,664
- Shares outstanding
- 130,081,000
- Ownership
- 59.04%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 0.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 180 | 41 | 80 | 73 | 53 | 66 | 83 | 37 | 33 | 64 | 49 | 46 | ||||||
| Debt Securities Current | 263 | 338 | 318 | 279 | 262 | 246 | 275 | 312 | 297 | 255 | 302 | 292 | ||||||
| Accounts And Other Receivables Net Current | 41 | 49 | 41 | 31 | 40 | 40 | 37 | 36 | 26 | 29 | 24 | 38 | ||||||
| Inventory Net | 45 | 46 | 46 | 45 | 47 | 46 | 39 | 39 | 39 | 40 | 40 | 33 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | 8 | 8 | 9 | 16 | ||||||
| Other Assets Current | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 3 | 7 | 2 | 1 | 2 | ||||||
| Assets Current | 541 | 480 | 492 | 439 | 409 | 406 | 447 | 440 | 410 | 398 | 425 | 426 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Deferred Income Tax Assets Net | 179 | 167 | 176 | - | - | - | 0 | - | - | - | - | - | ||||||
| Finance Lease Right Of Use Asset | 65 | 70 | 74 | 79 | 83 | 88 | 92 | 96 | 101 | 104 | 109 | 113 | ||||||
| Finite Lived Intangible Assets Net | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Debt Securities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Assets | 792 | 724 | 752 | 528 | 503 | 505 | 551 | 549 | 524 | 517 | 548 | 555 | ||||||
Liabilities | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | - | 57 | 56 | 50 | 54 | 52 | ||||||
| Accounts Payable Current | 2 | 3 | 3 | 2 | 3 | 4 | 5 | - | - | - | 4 | - | ||||||
| Accrued Liabilities Current | 64 | 58 | 67 | 50 | 50 | 42 | 65 | - | - | - | 50 | - | ||||||
| Finance Lease Liability Current | 16 | 17 | 17 | 16 | 16 | 15 | 14 | 15 | 14 | 14 | 15 | 13 | ||||||
| Contract With Customer Liability Current | 11 | 5 | 4 | 5 | 5 | 5 | 11 | 4 | 4 | 5 | 5 | 5 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 5 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | ||||||
| Liabilities Current | 100 | 87 | 94 | 76 | 78 | 68 | 98 | 79 | 77 | 71 | 77 | 74 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Finance Lease Liability Noncurrent | 44 | 48 | 52 | 56 | 59 | 57 | 59 | 66 | 65 | 67 | 75 | 72 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 13 | - | - | - | 2 | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 23 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Revenue Noncurrent | 7 | 12 | - | 12 | 12 | 12 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | ||||||
| Other Liabilities Noncurrent | 1 | - | 7 | - | - | - | 9 | 11 | 11 | 12 | 11 | 10 | ||||||
| Liabilities | 177 | 156 | 170 | 162 | 167 | 155 | 173 | 161 | 159 | 157 | 170 | 163 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value Outstanding | 1,117 | 1,087 | 1,120 | 1,117 | 1,123 | 1,163 | 1,188 | 1,207 | 1,206 | 1,208 | 1,200 | 1,199 | ||||||
| Additional Paid In Capital Common Stock | 76 | 97 | 111 | 110 | 105 | 101 | 127 | 120 | 112 | 105 | 121 | 110 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -578 | -615 | -649 | -860 | -892 | -913 | -937 | -938 | -952 | -953 | -942 | -915 | ||||||
| Stockholders Equity | 615 | 568 | 581 | 366 | 335 | 350 | 377 | 388 | 365 | 359 | 378 | 392 | ||||||
| Liabilities And Stockholders Equity | 792 | 724 | 752 | 528 | 503 | 505 | 551 | 549 | 524 | 517 | 548 | 555 | ||||||
| Related Party | - | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 133 | 131 | 132 | 132 | 133 | 138 | 141 | 143 | 143 | 144 | 144 | 144 | ||||||
| Shares Outstanding | 133 | 131 | 132 | 132 | 133 | 138 | 141 | 143 | 143 | 144 | 144 | 144 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAurinia Pharmaceuticals Inc. (AUPH) — SEC Financial Statements & Analysis
Aurinia Pharmaceuticals Inc. (AUPH) is a pharmaceutical preparations company. Aurinia Pharmaceuticals Inc. trades on Nasdaq as: AUPH. Aurinia Pharmaceuticals Inc. (AUPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Aurinia Pharmaceuticals Inc. carries a market cap of $2.21B, a P/E ratio of 7.03x, a P/B ratio of 3.59x, a P/S ratio of 7.09x, an enterprise value of $2.09B, and an EV/EBITDA multiple of 12.27x. On profitability, it posts a gross margin of 90.36%, an operating margin of 48.39%, a net margin of 100.84%, a Return on Equity (ROE) of 66.12%, a Return on Assets (ROA) of 48.52%, and a Return on Invested Capital (ROIC) of 34.87%. Per share, it reports EPS of $2.41, diluted EPS of $2.35, free cash flow per share of $1.31, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 19.76% year-over-year, net income growth of 418.03% year-over-year, and EPS growth of 437.12% year-over-year. On the balance sheet, it maintains a current ratio of 5.42x, a quick ratio of 4.97x, working capital of $441.43M, a debt-to-equity ratio of 0.29x, a debt ratio of 0.22, an interest coverage ratio of 36.71x, free cash flow of $170.03M (TTM), and net debt of $-119.41M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.21B
- P/E TTM
- 7.03x
- EPS TTM
- $2.41
- P/B TTM
- 3.59x
- ROE TTM
- 66.12%
- ROA TTM
- 48.52%
- Debt To Equity
- 0.29x
- Free Cash Flow TTM
- $170.03M
- Net Revenue TTM Growth 1Y
- 19.76%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aurinia Pharmaceuticals Inc. in?
Aurinia Pharmaceuticals Inc. (AUPH) operates in the Pharmaceutical Preparations industry.
What exchange does AUPH trade on?
Aurinia Pharmaceuticals Inc. (AUPH) trades on the Nasdaq.
When was Aurinia Pharmaceuticals Inc. (AUPH)'s most recent SEC filing?
Aurinia Pharmaceuticals Inc. (AUPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is AUPH's market cap?
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2.21B as of 2026-06-30.
What is AUPH's P/E ratio?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month P/E ratio is 7.03x as of 2026-06-30.
What is AUPH's EPS (earnings per share)?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month EPS is $2.41 as of 2026-06-30.
What is AUPH's ROE (return on equity)?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month Return on Equity (ROE) is 66.12% as of 2026-06-30.
What is AUPH's ROA (return on assets)?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month Return on Assets (ROA) is 48.52% as of 2026-06-30.
What is AUPH's ROIC (return on invested capital)?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month Return on Invested Capital (ROIC) is 34.87% as of 2026-06-30.
What is AUPH's EV/EBITDA?
Aurinia Pharmaceuticals Inc. (AUPH)'s trailing twelve month EV/EBITDA is 12.27x as of 2026-06-30.